Company Overview of Stemina Biomarker Discovery, Inc.
Stemina Biomarker Discovery, Inc., a metabolomics company, focuses on the discovery, development, and commercialization of molecular biomarkers to improve drug safety and human health. The company works on collaborative research projects and joint development agreements with strategic partners to develop drugs, identify targets, and discover molecular biomarkers for the diagnosis of diseases and customized treatment. It provides metabolomics and mass spectrometry services, as well as develops diagnostic biomarkers. The company’s cell-based assays arise from the strategic convergence of technologies, such as human embryonic stem (hES) cells and metabolomics. It uses mass spectrometry to analy...
504 South Rosa Road
Madison, WI 53719
Founded in 2006
Key Executives for Stemina Biomarker Discovery, Inc.
Chief Executive Officer and Director
Director of BioAnalytical Chemistry
Senior Scientist of BioAnalytical Chemistry
Compensation as of Fiscal Year 2015.
Stemina Biomarker Discovery, Inc. Key Developments
Stemina Biomarker Discovery, Inc. Launches Ever Clinical Study of Metabolism of Children with Autism
Sep 23 15
Stemina Biomarker Discovery Inc. announced the launch of the clinical study of the metabolism of children with autism spectrum disorder ever conducted. The Children’s Autism Metabolome Project or “CAMP” study will enroll 1,500 subjects from six sites across the country. CAMP will attempt to confirm that sets of metabolic biomarkers can detect subtypes of ASD. This new study is an expanded version of Stemina’s three pilot studies of more than 500 children. CAMP is also designed to contribute to identification of new biomarkers with the goal of advancing a panel of tests for earlier diagnosis and more precise treatment of ASD based on the metabolism of patients. Metabolomics is the study of differences in a person's metabolism as genomics is the study of differences in a person's genes. Metabolomics focuses on identifying normal and abnormal patterns of small molecules which indicate the presence of illness. Altered metabolism of patients offers more insight into the individual patient and potential treatments that may be effective based on the patient’s own metabolism. Stemina’s proprietary metabolomics technology is capable of identifying not only biomarkers associated with disease, but also metabolite patterns associated with toxicology and cellular response to drugs or chemicals this may be used in future studies to try to identify environmental factors associated with autism and other neurological disorders.
Stemina Presents at 2014 Autism Investment Conference, Mar-04-2014 09:00 AM
Feb 24 14
Stemina Presents at 2014 Autism Investment Conference, Mar-04-2014 09:00 AM. Venue: Bently Reserve, 301 Battery St, San Francisco, CA 94111, United States. Speakers: Marc Schneebaum, Head of Stemina Diagnostics.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries